Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts

Fig. 2

Tumor volume assessment during treatment. Tumor volume evolution in the UZLX-STS22 leiomyosarcoma, UZLX-STS39 malignant peripheral nerve sheath tumor, UZLX-STS59 myxofibrosarcoma and UZLX-STS84 undifferentiated pleomorphic sarcoma patient-derived xenograft model. Data are presented as relative tumor volume (%) compared to baseline. All data points are shown as mean ± standard deviation of at least seven tumors per treatment group. †: one UZLX-STS84-bearing mouse of the combination group sacrificed on day 13 due to a relative body weight of 85%, tumor volume before euthanasia included in the graph

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us